BlackRock’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

BlackRock’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,484	Closed	-$52K	–	3881
2016 Q3	$52K	Buy	2,484 +632	+34%	+$7.28K	﹤0.01%	2939
2016 Q2	$20K	Buy	1,852 +72	+4%	+$616	﹤0.01%	3276
2016 Q1	$11K	Buy	1,780 +1,577	+777%	+$14.3K	﹤0.01%	3140
2015 Q4	$4K	Hold	203	–	–	﹤0.01%	3231
2015 Q3	$2K	Hold	203	–	–	﹤0.01%	3178
2015 Q2	$3K	Hold	203	–	–	﹤0.01%	3202
2015 Q1	$2K	Buy	+203	New	+$2.74K	﹤0.01%	3136

BlackRock's VTAE Position: Q4 2016 in Review

BlackRock sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 2,484 shares — an estimated $52K sold.

BlackRock first reported a position in VTAE in Q1 2015 and held it in 7 quarters. The position peaked at $52K in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

BlackRock reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
BlackRock sold 2,484 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $52K.
BlackRock first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2015 and held it in 7 quarters.
BlackRock's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $52K in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on BlackRock's 13F filing for Q4 2016, filed 10 Feb 2017.